The NMPA has accepted the IND application of equecabtagene autoleucel for NMOSD. The application was based on ITT to evaluate the safety, tolerability, preliminary efficacy, PK, & PD of equecabtagene autoleucel in patients with refractory NMOSD
As of the cut-off date of Mar 2022, 12 patients received equecabtagene autoleucel cell reinfusion including 3 in 0.5×106 CAR-T cells/kg dose, 3 in 1.0×106 CAR-T cells/kg dose in the dose-escalation stage & 6 in expansion stage
In preliminary results, all patients experienced 1~2 CRS with no ICANS events, reduction in EDSS scores with improved visual acuity in 50% of patients, improved walking ability (67%) & bladder function (75%). The product is expected to be available to NMOSD patients shortly in China globally
Ref: IASO Biotherapeutics | Image: IASO Biotherapeutics
